Due to significant reduction in attack frequency,
severity and duration, nVNS can be used in CH patients who are intolerant to
multiple preventive and acute treatments.
Non-invasive vagus nerve stimulation emerges as an efficient and safe treatment approach to manage cluster headache (CH) during an early UK experience using real-world data.
The real-world data was extracted using the information of 30 CH patients from the UK who proffered individual funding applications for nVNS to the National Health Service. Each of the patients from the analysis responded to adjunctive nVNS therapy during 3–6 months of the evaluation period and physicians collected their experience in terms of notes, treatment diaries, and interviews. Statistical significance was assessed via paired t-tests.
A significant decrease was observed in CH attack
frequency (26.6 to 9.5 attacks/wk), duration (51.9 to 29.4 minutes), and severity
(7.8 to 6.0) after the introduction of nVNS therapy. There was a decrease in
use of abortive treatments. The device-related severe adverse events were also
not seen with preventive treatment. The practical use of nVNS therapy in
CH patients was suggested by the study findings which also complements the
results of clinical trials demonstrating safety and efficacy of nVNS therapy.
The Journal of Headache and Pain
Non-invasive vagus nerve stimulation for treatment of cluster headache: early UK clinical experience.
Juana Marin et al.
Comments (0)